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1. Introduction 
The concept of immune surveillance posits innate and adaptive immune cell mediated 
recognition and elimination of tumor cells, which express either tumor specific antigens 
or molecules by cellular stress. Both innate and adaptive immunity are important to 
inhibit tumor formation and rejection of transplanted tumors (Dunn et al., 2004; Pardoll, 
2003). Despite immune surveillance, tumors do progress. Therefore, new concept 
immunoediting provides complete explanation of immune system in cancers. 
Immunoediting has three phases against tumors including elimination, equilibrium and 
escape (Swann & Smyth, 2007). Elimination phase is similar to immune surveillance, 
where the immune system detects tumor cells and kills them. In the equilibrium phase, 
tumor cells become dormant, and the immune system selectively destroys susceptible 
tumor clones and prevents tumor progression. In the escape phase, immune responses fail 
to suppress the tumor growth which leads to development of tumor variants that are 
resistant to anti-tumor responses. The major immune cells involved in targeting the tumor 
mass are CD8 T cells (MHC I dependent) and NK cells (MHC I independent/deficient) 
(Pardoll, 2003; Smyth et al., 2000, 2001). Perforin and Fas/FasL pathways constitute for 
contact-mediated cytotoxicity represented by NK and CD8 T cells (Lieberman, 2003; 
Russell & Ley, 2002). Also, other pathways play an important role in tumor elimination, 
such as IFN-Ǆ and IFN-ǂ/ǃ. Regulatory T cells have been initially described in studies by 
Sakaguchi et al who proved the role of (CD4+CD25+) regulatory T (Treg) cells in 
maintaining the tolerance against self-antigens (Sakaguchi et al., 1995, 2004, 2008). Treg 
cells have been shown to contain distinct populations (Table 1) which are able to actively 
suppress the function of other immune cells, including CD4+CD25- T cells, CD8 T cells, 
dendritic cells, macrophages, B cells, NK cells and NKT cells (Azuma et al., 2003; Chen, 
2006; Lim et al., 2005; Murakami et al., 2002; Romagnani et al., 2005; Trzonkowski et al., 
2004). Several studies recently proved that Treg cells could induce tolerance against 
tumors (Nagai et al., 2004; von Boehmer, 2005; Yamaguchi & Sakaguchi, 2006). Also, 
studies addressed the expansion of Treg cells in various non-hematological and 
hematological malignancies (Beyer & Schultze, 2006b). Treg cells were also proved to 
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inversely correlate with outcome of various cancers, including gastric malignancies, 
ovarian and breast cancers (Curiel et al., 2004; Merlo et al., 2009; Sasada et al., 2003). 
However, it appears that in certain diseases, such as follicular lymphoma and Hodgkin’s 
lymphoma, higher number of FoxP3+ cells correlate with better survival (Alvaro et al., 
2005; Carreras et al., 2006).  
Multiple myeloma is a plasma cell proliferative disorder and the second most common 
hematological malignancy standing next to lymphoma (Kyle & Rajkumar, 2008). Multiple 
myeloma is clinically characterized by ≥ 10% of plasma cell infiltration in the bone 
marrow, ≥ 30g/L of monoclonal protein and presence of CRAB symptoms 
(hypercalcemia, renal insufficiency, anemia and bone lytic lesions) (Raja et al., 2010). It has 
been proved that B and T lymphocyte populations in multiple myeloma significantly 
associate with survival (Kay et al., 2001). Multiple myeloma patients commonly present 
with defects in numbers and function of various immune cells including dendritic cells, B 
cells, T cells and NK cells (Pratt et al., 2007). Concept of immunoediting also fits in 
multiple myeloma because of its several stages, starting from premalignant stage known 
as monoclonal gammopathy of undetermined significance to symptomatic stage (Swann 
& Smyth, 2007). Elimination phase of immunoediting has been explained in premalignant 
stage of myeloma, where strong T cell response was observed against the tumor clone 
compared to malignant stage (Dhodapkar, 2005). Followed by surveillance, T cells patrol 
the premalignant clone (equilibrium) and finally lose responses against malignant clones 
which lead to symptomatic myeloma (escape) (Dhodapkar et al., 2003). Recently, in 
multiple myeloma several studies showed elevated level of Treg cells; these cells were 
functionally active in suppressing the function of naïve T cells. In this chapter, we focus 
on describing general aspects of Treg cells, including subtypes, functions, migration and 
induction of tolerance at tumor microenvironment. Then, we discuss the role of CD4 Treg 
cells in multiple myeloma and their association with stages and survival, and influence of 
immunomodulatory drugs on multiple myeloma patient’s Treg cells. Additionally, we 
discuss the role of Th17 cells, CD8 Treg cells and myeloid-derived suppressor cells 
(MDSCs) in multiple myeloma. 
2. Phenotypic characterizations of regulatory T cells in humans 
In mice, CD4 Treg cells can be easily characterized as CD4+FoxP3+ and high expression of 
CD25 (Sakaguchi et al., 1995). However, identification of human Treg cells is ambiguous 
because approximately 1-2 % of CD25 expressing T cells are functional Treg cells (Allan et 
al., 2005; Baecher-Allan et al., 2001). Isolation of CD25hi T cells excludes FoxP3 low and 
CD25 low/intermediate Treg cells which are found to be naïve Treg cell population 
(CD45RA+/CD45RO-). Unclear identification of CD25 (intermediate and high) expression 
on CD4 Treg cells influence the reproducibility of results in various disorders. Several 
groups suggested that negative expression of CD127 in Treg cells might help in 
characterization. But it will not ensure the accurate identification of Treg cells because 
activated CD4 T cells are also CD127- (Liu et al., 2006; Seddiki et al., 2006). Alternatively, 
CD62L expression could differentiate the recently activated CD4 T cells (CD62L low) and 
Treg cells (CD25hi+CD62L+CD127low) but CD62L expression is not solely restricted to 
Treg cells (Hamann et al., 2000). Characterization of Treg cells using the CD127 and CD25 
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does not exclude the non-regulatory Foxp3 expressing T cells. These cells express 
CD45RO, lack suppressive ability and secrete pro-inflammatory cytokines IL-2, IFN-Ǆ and 
IL-17 (Miyara et al., 2009). In conclusion, heterogenic expression of FoxP3 by non-
regulatory and Treg cells precludes the inclusion of FoxP3 as a sole marker in humans to 
characterize the Treg cells. 
3. Types and functions of T regulatory cells 
The existence of Treg cells was uncovered more than four decades ago in studies showing 
that neonatally thymectomized mice developed autoimmunity, which could be prevented 
by reconstitution with CD4 T cells (Nishizuka & Sakakura, 1969; Sakaguchi et al., 1982). 
Further work characterized these Treg cells as CD4+ T cells expressing high levels of IL-2 
receptor ǂ chain (Sakuguchi et al., 1995). Fontenot et al determined that in mice, forkhead 
transcription factor FoxP3 is a specific marker of Treg cells and a master regulator in 
development and function of Treg cells (Fontenot et al., 2003). Types and functions of 
various Treg cells are summarized in Table 1 and Table 2. 
 
Types Origin Functions References 
CD4+ natural 
regulatory  
T cells 
Arise in thymus 
and disseminate to 
periphery; 
constitute about 
10%-15% of CD4 
cells 
In mice, depletion of these cells leads 
to autoimmunity. In humans, 
mutation in FoxP3 gene located on  
X chromosome leads to fatal immune 
disorder IPEX syndrome (Immune 
dysregulation, 
Polyendocrinopathy, Enteropathy,  
X-linked syndrome) 
Gambineri  
et al., 2003. 
CD4+ Tr1 
regulatory 
cells 
Periphery 
Induced in the periphery from naïve 
T cells in the presence of IL-10. These 
cells lack FoxP3 expression but 
secrete IL-10 and TGF-ǃ. 
Groux  
et al., 1997;  
Vieira  
et al., 2004 
CD4+ Th3 
cells 
Periphery 
Induced in the periphery from naïve 
T cells in the presence of TGF-ǃ. 
Suppression is mediated by TGF-ǃ. 
Rare Th3 cells express FoxP3 
molecule due to induction  
by TGF-ǃ. 
Apostolou & 
von Boehmer, 
2004;  
Chen et al., 
2003. 
Double 
negative Treg 
cells 
Periphery 
In mice and humans these cells 
constitute about 1%-3% and 1%, 
respectively. Double negative Treg 
cells inhibit T cell activation and 
proliferation in an antigen specific 
manner. 
Fischer  
et al., 2005. 
Ǆǅ T cells Infiltrate into tumor 
site (breast cancer)
Suppress naïve and effector T cell 
responses and inhibit maturation and 
function of dendritic cells. 
Peng  
et al., 2007. 
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Types Origin Functions References 
CD8 
regulatory  
T cells 
Most of CD8 Treg 
cells are induced by 
antigen- specific 
manner 
There are several subsets of CD8 Treg 
cells: Qa-1 specific CD8 Treg cells 
suppress autoreactive T cells 
expressing Qa-1 molecule associated 
with self peptide. CD8+CD28- Treg 
cells express FoxP3ǂ molecule and 
suppress other cells via contact 
dependent mechanism. CD8+CD25+ 
Treg cells suppress both naïve CD4 
and CD8 T cells by contact dependent 
or independent (IL-10) mechanisms. 
CD8+CD25+ Treg cells mostly 
accumulate in the tumor bed rather 
than peripheral 
tissues. 
Filaci  
et al., 2007; 
Kiniwa  
et al., 2007; 
Sarantopoulos 
et al., 2004; 
Wang, 2008. 
 
Table 1. Subsets of T regulatory cells 
 
Functions of 
Treg cells 
Mechanism of Suppression References 
Inhibitory 
cytokines 
Mainly cytokines such as IL-10, TGF- ǃ and IL-35 secreted 
by Treg cells are involved in inhibitory function. Chen et al 
proved in murine colon carcinoma IL-10 induced 
suppression of tumor specific CD8 T cell immunity. 
Peptide inhibitor targeted against the surface TGF-ǃ on 
Treg cells abrogated their function and enhanced anti-
tumor response. In mouse model of inflammatory bowel 
disease, it was shown that IL-35 played a role in severity of 
inflammatory bowel disease. In humans IL-35 is not 
expressed constitutively by Treg cells. 
Bardel  
et al., 2008; 
Chen  
et al., 2005; 
Collison  
et al., 2007; 
Gil-Guerrero  
et al., 2008; 
Loser  
et al., 2007. 
Cytotoxicity 
Perforin/granzyme pathway is well known to be 
associated with CD8 T cells and NK cells for destruction of 
intracellular pathogens and tumor cells. Recent studies 
have shown Treg cells also use the perforin/granzyme 
pathway. An in vitro study demonstrated Treg cells 
activated with anti CD3 and anti CD46 antibodies 
expressed granzyme A and B. In murine Treg cells, it was 
shown that perforin lacking Treg cells also exhibit 
suppressive function. Cao et al reported in a tumor 
inoculation system the adoptively transferred Treg cells 
induced suppression of tumor immunity (CD8 T cells and 
NK cells) specifically by granzyme B pathway. Fas ligand 
utilizing Treg cells presence was reported in head and 
neck squamous cell carcinoma patients and found to 
suppress CD8 T cells. 
Cao  
et al., 2007; 
Gondek  
et al., 2005; 
Grossman  
et al, 2004; 
Lieberman, 
2003;  
Russell & 
Ley, 2002; 
Strauss  
et al., 2009. 
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Functions of 
Treg cells 
Mechanism of Suppression References 
Inhibition of 
antigen 
presenting cells 
(APCs) 
Expression of CTLA-4 under the control of FoxP3 
facilitates Treg cells interaction with CD80 and CD86 on 
APCs and induces the suppression of T cell activation. 
CTLA-4 mediated interaction between Treg cells and 
APCs leads to upregulation of indoleamine 2, 3- 
dioxygenase (IDO) production by the APCs which leads to 
degradation of the essential amino acid tryptophan. 
Recently, it was proposed that IDO mediated depletion of 
tryptophan inhibited T cell proliferation and response 
against tumors. 
Mellor & 
Munn, 2004; 
Munn  
et al., 1999; 
Oderup  
et al., 2006; 
Read  
et al., 2000. 
Table 2. Functions of T regulatory cells 
4. Mechanism of migration and induction of tolerance in the tumor bed by 
regulatory cells 
There are several chemokine receptors and ligands are involved in the migration of Treg 
cells. Before going into detail, we would like to summarize the migration process of Treg 
cells from thymus to secondary lymphoid organ in normal physiological conditions. 
Preliminary switch occurs in chemokine receptors CCR8/CCR9 and CXCR4 to CCR7 on 
thymic precursors of Treg cells. These precursor Treg cells are a homogeneous population 
and express CD62L, CCR7 and CXCR4low (Lee et al., 2007). After migration from thymus to 
the periphery, these Treg cells acquire complete expression of CXCR4. Thymic emigrant 
Treg cells most exclusively migrate to secondary lymphoid organ for antigen contact. After 
the antigen contact, the second switch occurs in the receptors where they downregulate the 
CCR7 and CXCR4 expression. Consequently, upregulation of effector/memory chemokine 
receptors (CCR2, CCR4, CCR6, CCR8, and CCR9) occurs to enhance the heterogenic 
property of Treg cell population (Lee et al., 2007). It was shown that CCR7 mediated 
migration of Treg cells into secondary lymphoid organ is an important process for 
encountering mature dendritic cells and consequent differentiation and proliferation 
(Schneider et al., 2007). All peripheral blood Treg cells express CCR4 receptor and show 
chemotactic response to ligands CCL22 and CCL17. In ovarian cancer, Treg cell migration 
and accumulation at the tumor site is attributed by CCL22 chemokine (Curiel et al., 2004). 
Secretion of CCL22 by lymphoma cells largely recruits the intratumoral Treg cells that 
express CCR4 but not CCR8 (Ishida et al., 2006; Yang et al., 2006b). In non-hematological 
malignancies, it was observed that increased frequency of CCR4 expressing Treg cells 
associated with CCL22 and CCL17 chemokines. An in vitro study in gastric cancer showed 
that migratory activity of Treg cells was induced by CCL22 and CCL17 chemokines 
(Mizukami et al., 2008). 
Several molecules and receptors contribute the suppressive function of Treg cells in the 
tumor microenvironment. Suppression mechanism by Treg cells is not solely dependent on 
cell-cell contact rather it is also supported by soluble IL-10 and TGF-ǃ molecules (Strauss et 
al., 2007). Treg cells do not depend always on direct inhibition of effector T cells; rather, it 
impedes function of dendritic cells via IL-10 and TGF-ǃ. This mechanism downregulates 
NF-kB and subsequently changes downstream molecules (CD80, CD86 and CD40) as well as 
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soluble factors, such as TNF-ǂ, IL-12 and CCL5 (Larmonier et al., 2007). Moreover, Treg cells 
in tumor bed prevent CD4 T cell mediated generation of CD8 T cell cytotoxic responses 
(Chaput et al., 2007). Prostaglandin E2 is the effector molecule released by Treg cells; it is 
also important for activation of Treg cells. This molecule efficiently suppresses the effector T 
cell responses via COX2 induction. Prostaglandin E2 mediated suppression by Treg cells 
was observed in colorectal cancer patients (Mahic et al., 2006). Cell-cell contact dependent 
suppression is partly attributed to CTLA-4 expression by Treg cells (Read et al., 2000). 
Expression of CTLA-4 also facilitates the TGF-ǃ mediated suppression via intensifying the 
TGF-ǃ signals at the interaction point of Treg cell and target cell (Oida et al., 2006). Tumor 
infiltrating Treg cells express ICOS molecule but peripheral Treg cells do not express ICOS. 
ICOS receptor and its ligand are involved in Treg cell mediated suppression. Treg cells with 
ICOS low expression did not show strong suppressive function as compared to Treg cells 
with ICOS high expression (Strauss et al.,  2008). Very recently, other novel  
 
Fig. 1. Mechanism of accumulation and expansion of T regulatory cells in the tumor bed  
This schematic diagram represents a mechanism of immune tolerance induced by Treg cells 
in the tumor microenvironment. CCL22 as well H-ferritin secretion by tumor cells and 
tumor infiltrating macrophages recruit naïve Treg cells (CCR4+) in the tumor bed. These 
accumulated naïve Treg cells differentiate and proliferate into memory Treg cells via 
interaction with prostaglandin E2 (PGE2) induced tolerogenic dendritic cells. These 
expanded memory Treg cells along with tolerogenic dendritic cells impede the functions of 
tumor effector T cells.  
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mechanisms of suppression by Treg cells were revealed. Expression of CD39 in 
conjunction with CD73 generates the adenosine molecule and its interaction with 
adenosine A2A receptor on activated T cells creates strong immunosuppressive loops; this 
suggests one of the important suppressive mechanisms of Treg cells (Deaglio et al., 2007). 
Transfer of cyclic adenosine monophosphate by Treg cells to effector T cells via cell-cell 
interaction induces suppression and impedes IL-2 secretion (Bopp et al., 2007). Also, 
recently it was proven that effector T cells are suppressed via apoptosis induced by 
deprivation of Ǆ cytokines by Treg cells. Strong association was observed between Treg 
cell induced apoptosis and increased level of pro-apoptotic proteins Bim and Bad as well 
as decreased level of pro-survival protein kinase Akt (Pandiyan et al., 2007). Taking all 
these observations into consideration, the significance of chemokines and their receptors 
in migration of Treg cells could act as a suitable target for deprivation of Treg cells in the 
tumor microenvironment; this might also enhance anti-tumor responses. To add more 
flavors in impeding Treg cell migration, a chimeric monoclonal antibody targeting CCR4 
receptor is already under clinical trial. All of the above mentioned mechanisms of 
suppression collectively work together to induce suppression of immune cells and 
tolerance in the tumor bed. In some circumstances, these mechanisms might 
independently act to enforce the suppression of anti-tumor responses. 
5. Regulatory T cells and multiple myeloma 
Recently, several research groups analyzed Treg cells in multiple myeloma. So far, Treg cells 
data in multiple myeloma are conflicting. Study from Prabhala et al and Gupta et al 
reported decreased frequency of peripheral blood Treg cells in multiple myeloma when 
compared to control group (Gupta et al., 2011; Prabhala et al., 2006). Both studies confirmed 
that FoxP3 expression was reduced in myeloma patients. In contrast to these studies, Feyler 
et al and Beyer et al reported increased frequencies of peripheral blood Treg cells in multiple 
myeloma patients (Feyler et al., 2009; Beyer et al., 2006a). Most of the studies confirmed that 
peripheral blood and bone marrow Treg cells frequencies were comparable. According to 
Beyer et al, Treg cells associated markers, such as CTLA-4, GITR, CD62L and OX40 were 
elevated in myeloma patients compared to healthy subjects (Beyer et al., 2006a). Contrasting 
to this observation, Prabhala et al showed decreased frequency of CTLA-4 expression on 
Treg cells of monoclonal gammopathy of undetermined significance and myeloma cohorts 
than healthy subjects (Prabhala et al., 2006). These opposing results may be due to Treg cells 
identification strategy. For instance, Prabhala et al identified Treg cells as CD4+FoxP3+, 
Gupta et al characterized Treg cells with the inclusion of CD127 in their gating, Feyler et al 
identified Treg cells as CD4+CD25hi+FoxP3+ and Beyer et al identified Treg cells using only 
CD4 and CD25 markers (Beyer et al., 2006a; Feyler et al., 2009; Gupta et al., 2011; Prabhala et 
al., 2006). Most of the studies in other cancers including hematological and non-
hematological malignancies showed elevated level of Treg cells and these cells are 
associated with worse prognosis. To support the concept of tumor based expansion of Treg 
cells, studies clearly showed that established Treg cell clones recognized tumor antigen in 
MHC class II restricted manner (Wang et al., 2004). In multiple myeloma, no strong 
conclusions could be made due to the existence of equal number of conflicting results with 
regard to Treg cells frequency.   
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5.1 Immunosuppressive function of T regulatory cells in multiple myeloma 
Most studies in myeloma agree that Treg cells efficiently suppress both autologous and 
allogeneic responder cells (CD4+CD25-) similarly to healthy subjects (Beyer et al., 2006a; 
Brimnes et al., 2010; Feyler et al., 2009; Gupta et al., 2011). Exclusively, Prabhala et al showed 
that multiple myeloma patients Treg cells lack suppressive function (Prabhala et al., 2006). 
This contrasting result by Prabhala et al might be due to the use of whole peripheral blood 
mononuclear cells depleted with CD25+ cells as responder cells (Prabhala et al., 2006). The 
suppressive nature of Treg cells could be well appreciated by the presence of intracellular 
cytokines TGF-ǃ and IL-10. Beyer et al confirmed that myeloma patients Treg cells express 
increased level of TGF-ǃ and IL-10 when compared to healthy subjects (Beyer et al., 2006a). 
In vitro matured dendritic cells using inflammatory cytokines generate functionally active 
FoxP3+ Treg cells from CD25- T cells. Treg cells derived from dendritic cells are functionally 
similar in between healthy subjects and myeloma patients. Also, an in vivo study showed 
administration of cytokine matured dendritic cells in myeloma subjects enhanced increase of 
Treg cell numbers (Banerjee et al., 2006). This study also proposed that use of human 
dendritic cell vaccination may affect the balance of effector T cells generation because of 
Treg cell enhancement (Banerjee et al., 2006). In allogeneic stem cell transplanted multiple 
myeloma patients, donor derived Treg cells reconstituted largely in the bone marrow 
compartment and prevented graft versus host disease (Atanackovic et al., 2008). This data 
suggest that in vivo inhibitory function of Treg cells and also in vitro assay showed 
reconstituted Treg cells possess complete inhibitory function. Moreover, Atanackovic et al 
proved that reconstitution of Treg cells in bone marrow positively correlates with time 
passed since transplantation. Donor derived Treg cells reconstituted in the bone marrow 
were found to be memory Treg cells, which indicates that Treg cells indeed expanded 
outside the thymus (Atanackovic et al., 2008). Most of the studies strongly suggest that 
myeloma patients Treg cells are functional in suppressing the conventional T cell 
proliferation, and this suppressive function encourages the immune impairments and 
dysfunctions. However, Treg cells suppressive function could be appreciated in the case of 
graft versus host disease where donor cells require engraftment to ensure the anti-tumor 
effects. 
5.2 Association of international staging system and myeloma survival status with  
T regulatory cells 
Based on the international staging system (ISS), Treg cells were increased in newly 
diagnosed multiple myeloma patients. This observation was noticed only in ISS 1 and ISS 2 
(Feyler et al., 2009). On the other hand, Gupta et al found a trend of decrease in Treg cells in 
stages ISS 2 and ISS 3 (Gupta et al., 2011). Apart from ISS, paraprotein level of myeloma 
patients was positively correlated with frequencies of Treg cells (Feyler et al., 2009). 
Giannopoulos et al demonstrated patients with higher level of Treg cells have significantly 
reduced survival time compared to patients with lower level of Treg cells (21 months vs. 
median not reached) (Giannopoulos et al., 2010). Our observation also showed that patients 
with increased peripheral blood Treg cells (≥ 5%) have shorter progression free survival 
compared to patients with reduced Treg cells (< 5%) cohort (13 months vs. median not 
reached) (Muthu Raja et al., 2011). These data showing that elevated level of Treg cells 
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correlated unfavorably with progression free survival and overall survival of myeloma 
patients, so Treg cells could be targeted along with the tumor cells in multiple myeloma.  
6. Influence of immunomodulatory drugs on T regulatory cells of multiple 
myeloma patients 
Immunomodulatory drugs are orally bioavailable agents, derived from thalidomide (first 
generation immunomodulatory drug). The second generation immunomodulatory drugs 
are lenalidomide and pomalidomide which share similar chemical structure with 
thalidomide (Galustian et al., 2004). Quach et al recently reviewed the functions of 
immunomodulatory drugs (Quach et al., 2010). The functions are:  
6.1 Immune modulation 
Co-stimulation of CD4 and CD8 T cells, activation of NK and NKT cells, production of Th1 
cytokines, enhancement of antibody dependent cellular cytotoxicity and Treg cell 
suppression. 
6.2 Hampering tumor microenvironment interactions 
Anti-angiogenesis, inhibition of inflammatory effects, anti-osteoclastogenesis and 
downregulation of adhesion molecules on plasma cells. 
6.3 Direct anti-tumor effects 
Induction of cyclin dependent kinase inhibitors, such as p15, p21 and p27 which results in 
cell cycle arrest (G0/G1 phase), increases expression of early growth genes (1, 2), 
downregulation of NF-kB with subsequent reduction in anti-apoptotic proteins FLIP and 
clAP2. 
Minnema et al showed that in relapsed myeloma patients (after allogeneic stem cell 
transplantation), lenalidomide increased frequencies of Treg cells during treatment 
(Minnema et al., 2009). In contrast, CD4 and CD8 T cells were decreased. This study also 
showed that ratio of FoxP3+ T cells to IFN-Ǆ secreting T cells was significantly increased 
during treatment (Minnema et al., 2009). Increased Treg cells always favour allogeneic stem 
cell transplanted patients because these cells inhibit graft versus host disease (Rezvani et al., 
2006). However, Minnema et al study did not show the advantage of increased Treg cells 
with relevance to graft versus host disease, probably due to small patient numbers 
(Minnema et al., 2009). Contrasting to this study, an in vitro observation demonstrated that 
lenalidomide and pomalidomide are able to inhibit the proliferation of Treg cells at very low 
concentrations (10 μM and 1 μM) but thalidomide failed to inhibit the proliferation even at 
maximum concentration of 200 μM. This study reveals lenalidomide and pomalidomide 
inhibited the Treg cells mediated suppression of CD4+CD25- cells and also proposes that 
FoxP3 molecule was targeted efficiently by lenalidomide and pomalidomide but no 
alterations to GITR were observed (Galustian et al., 2009). Lenalidomide and pomalidomide 
also inhibit the function of Treg cells by hindering the expression of OX-40 (CD134) 
molecule (Galustian et al., 2009; Valzasina et al., 2005). Carcinoma animal model study 
showed Treg cells were depleted after cyclophosphamide treatment; tumor growth was also 
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repressed due to depletion of Treg cells, and tumor clones were cleared followed by 
immunotherapy. Without administration of cyclophosphamide, no tumor regression or 
clearance was noticed in the tumor bearing animal (Ghiringhelli et al., 2004). Apart from 
sensitivity of Treg cells to imunomodulatory drugs and cyclophosphamide, a recent study 
showed that naturally occurring Treg cells were resistant to pro-apoptotic effect of 
proteasome inhibitor bortezomib. Long-term culturing of CD4 T cells in the presence of 
bortezomib promoted the emergence of Treg cells and significantly inhibited proliferation, 
IFN-Ǆ production and CD40L expression by effector T cells (Blanco et al., 2009). Drug-
induced apoptosis resistance by Treg cells is due to the increased expression of BCL-2 and 
inhibitor of apoptosis protein 1 (IAP1); the expression of IAP1 is in response to TNF induced 
apoptosis. These BCL-2 and IAP1 protein expression was significantly elevated in Treg cells 
of B cell leukemic patients than healthy volunteers (Jak et al., 2009). Gupta et al confirmed 
that multiple myeloma patients treated with immunomodulatory drug combination showed 
increased Treg cells in relation to irrespective of the response achieved (Gupta et al., 2011). 
They also showed patients with stable and progressive disease had decreased Treg cells. 
Taking all these observations into consideration, no strong conclusion can be forwarded 
because of contrasting results between in vitro and in vivo studies. However, in vitro studies 
showed promising effects of immunomodulatory drugs on Treg cells when compared to 
proteasome inhibitor but immunomodulatory drugs effects might be diluted by inclusion of 
corticosteroid during treatment.  
7. Th17 cells in multiple myeloma  
Th17 cells are one of the subsets of CD4 T cells. These cells are differentiated in the presence 
of IL-6, IL-1ǃ, IL-21 and IL-23 with or without TGF-ǃ. Th17 cells secrete IL-17, IL-21, IL-22 
and IL-26 cytokines. These cytokines are involved in anti-fungal and anti-parasite responses 
and participate in inflammatory and autoimmune reactions (Acosta-Rodriguez et al., 2007; 
Aujla et al., 2008; Bettelli et al., 2006; Ivanov et al., 2006; Veldhoen et al., 2008; Wilson et al., 
2007; Zheng et al., 2008). Both Treg cells and Th17 cells originate from naïve CD4 T cells. For 
Treg cell differentiation, TGF-ǃ is required whereas for Th17 cell differentiation, IL-6 and 
TGF-ǃ are required (the role of TGF-ǃ in human is unclear) (Bettelli et al., 2006; Veldhoen et 
al., 2006). Xu et al observed that mature Treg cells can be converted into Th17 cells in the 
presence of IL-6 (Xu et al., 2007). IL-6 and IL-21 might be involved in transition of 
Th17/Treg cells to Th17 cells. Some reports show switching of Th17 cells to Th1 cells, but 
reverse switching is not possible (Annunziato & Romagnani, 2009; Bending et al., 2009; Lee 
et al., 2009; Shi et al., 2008). Upregulated T-bet expression in Th17 cells resulted in a switch 
to Th1 cells in the presence of IL-12 or/and IL-23 (Annunziato et al., 2007; Lee et al., 2009). 
Recently, a study reported increased Th17 cells and IL-17 in freshly isolated mononuclear 
cells and sera of myeloma patients compared to healthy subjects. In vitro polarization of 
CD4 T cells to Th17 cells showed increased Th17 cells in multiple myeloma patients than 
healthy subjects (Prabhala et al., 2010). Moreover, this study showed expression of IL-17 
receptor on myeloma cells which promotes the growth of myeloma cells. IL-21 is a pro-
inflammatory cytokine associated with Th17 cells, which is also capable of inducing STAT-3 
mediated myeloma growth-promoting effects in synergism with insulin like growth factor-1 
(Brenne et al., 2002). Most of the myeloma patients present with bone lytic disorder. In cell 
culture experiments, Dhodapkar et al showed dendritic cells were efficient inducers of Th17 
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cells, especially mature dendritic cells. Dendritic cells induced Th17 cells were 
multifunctional and secreted IL-17 and IFN-Ǆ (Dhodapkar et al., 2008). In myeloma, tumor 
cells are infiltrated by dendritic cells; Dhodapkar et al demonstrated that Th17 cells were 
enriched in the tumor microenvironment (Dhodapkar et al., 2008). These IL-17 producing 
cells were found to enhance the activation of osteoclasts (Noonan et al., 2010). This study 
also reported significant association between extent of bone lytic lesions and IL-17 cytokine 
producing Th17 cells (Noonan et al., 2010). These findings suggest that Th17 cells enhance 
myeloma cell growth and development of bone lytic lesions. 
8. CD8 T regulatory cells in multiple myeloma 
T cells play an important role in immunosurveillance against cancers. Eventually, these T 
cells may become CD4/CD8 regulatory T cells due to stimulation by and interaction with 
tumor cells. Thus, these generated regulatory cells promote the growth of tumor rather than 
inhibition of tumor (Wang, 2008). Mechanisms of suppression and expansion are well 
documented for CD4 Treg cells but recent research has been directed to screen the presence 
of CD8 Treg cells in various tumors and inflammatory conditions. 
8.1 Subtypes of CD8 T regulatory cells 
8.1.1 Qa-1 restricted CD8 Treg cells 
These CD8 Treg cells downregulate autoimmune T cell responses. They are Qa-1 (MHC class 
1b molecule) restricted and specifically target self-reactive activated T cells which express Qa-1 
molecules associated with self peptide (Jiang & Chess, 2004; Sarantopoulos et al., 2004). 
8.1.2 CD8+CD28- Treg cells 
These cells are induced by MHC class I peptide antigens. CD8+CD28- Treg cells were found 
to express FoxP3 ǂ molecule and mediate suppression by cell-cell contact mechanism. 
CD8+CD28- Treg cells also indirectly target CD4 T cells to become tolerogenic via dendritic 
cells and non-professional antigen presenting cells. These cells were identified in tumors as 
well as in the context of transplantation (Cortesini et al., 2001; Filaci & Suciu-Foca, 2002; 
Filaci et al., 2007; Suciu-Foca et al., 2005). 
8.1.3 CD8+CD25hi+ Treg cells 
These cells express CD122, Foxp3 and GITR molecules typically associated with CD4 Treg 
cells (Cosmi et al., 2003; Kiniwa et al., 2007; Lee et al., 2008). They suppress naive CD4 and 
CD8 T cells via contact dependent mechanism or soluble IL-10. These Treg cells are different 
from Qa-1 specific CD8 Treg cells but similar to CD4 Treg cells. CD8+CD25hi+ Treg cells are 
induced by the tumor environment and require antigen stimulation to suppress naïve T cells 
(Wang, 2008). 
8.2 Role of CD8 T regulatory cells  
So far, only a few studies have documented the role of CD8 Treg cells 
(CD8+CD25hi+FoxP3+) in cancers. In prostate and colorectal cancers, elevated levels of CD8 
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Treg cells have been reported (Chaput et al., 2009; Kiniwa et al., 2007). Both these studies 
showed that CD8 Treg cells are capable of suppressing naïve T cell proliferation. 
Additionally, Chaput et al demonstrated suppression of Th1 cytokine production. CD8 Treg 
cells from colorectal cancer patients were found to correlate with disease stage and micro-
invasive status (Chaput et al., 2009). In multiple myeloma, data on CD8 Treg cells are 
lacking. Our recent observation showed that CD8 Treg cells were significantly elevated in 
monoclonal gammopathy of undetermined significance and multiple myeloma when 
compared to healthy subjects (Muthu Raja et al., 2010). However, functional data of CD8 
Treg cells are still lacking. 
9. Myeloid-derived suppressor cells (MDSCs) in multiple myeloma 
Myeloid-derived suppressor cells (MDSCs) are activated immature myeloid cells that have 
been prevented from differentiation to mature cells. These cells are expanded in 
pathological conditions (Gabrilovich & Nagaraj, 2009). MDSCs lack the expression of cell 
surface markers that are specifically expressed by monocytes, macrophages or dendritic 
cells and comprise a mixture of myeloid cells that have the morphology of granulocytes or 
monocytes (Youn et al., 2008). They are potent suppressors of T cells. Human MDSCs can be 
characterized phenotypically as CD14-CD11b+ or by CD33 expression which is a common 
marker for myeloid cells. Moreover, MDSCs lack the expression of mature lymphoid and 
myeloid markers as well HLA-DR (MHC class II). Healthy individuals were found to have 
approximately 0.5% of immature myeloid cells from total peripheral blood mononuclear 
cells (Gabrilovich & Nagaraj, 2009). In cancer patients and tumor models, accumulation of 
MDSCs occurs due to release of soluble factors by tumor cells or cells in tumor environment 
(Almand et al., 2001, Diaz-Montero et al., 2009). 
9.1 Mode of suppression 
9.1.1 Arginase and inducible nitric oxide synthase 
Arginase and inducible nitric oxide synthase enzymes are released by MDSCs. Arginase 
depletes the non-essential amino acid L-arginine and leads to inhibition of T cell proliferation 
(Rodriguez et al., 2002). Inducible nitric oxide synthase mediates nitric oxide production. Nitric 
oxide suppresses the T cell function via induction of apoptosis, inhibition of MHC II expression 
and inhibition of STAT-5 and JAK3 function in T cells (Gabrilovich & Nagaraj, 2009). 
9.1.2 Reactive oxygen species  
This is also an important factor from MDSCs that contributes to suppressive activity. 
Reactive oxygen species release was noticed in tumor bearing mice and cancer patients. 
Several tumor derived factors including TGF-ǃ, IL-6, IL-3, IL-10 and granulocyte 
macrophage colony-stimulating factor induce reactive oxygen species synthesis by MDSCs 
(Gabrilovich & Nagaraj, 2009). 
9.1.3 Peroxynitrite  
Peroxynitrite induces MDSCs mediated suppression of T cell function. Accumulation of 
peroxynitrite is noticed where recruitment of MDSCs occurs at the site of inflammation or 
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immunological reactions. In addition, increased peroxynitrite levels associated with tumor 
progression in several cancers (Gabrilovich & Nagaraj, 2009). Interaction of peroxynitrite 
producing MDSCs and T cells leads to nitration of T cell receptors and alters specific peptide 
binding of T cells. This process leads to T cell unresponsiveness (Nagaraj et al., 2007). 
9.1.4 Induction of Treg cells 
In vivo studies showed that MDSCs can induce de novo generation of Treg cells (Huang et al., 
2006; Yang et al., 2006a). Induction of Treg cells by MDSCs requires tumor specific T cells 
together with IFN-Ǆ and IL-10, but independent of nitric oxide production (Huang et al., 
2006). In murine models, MDSCs induce generation of Treg cells by CTLA-4 (ovarian tumor) 
and arginase 1 (lymphoma) molecules (Serafini et al., 2008; Yang et al., 2006a). However, in 
contrast, other studies report no association of Treg cell generation with MDSCs (Dugast et 
al., 2008, Movahedi et al., 2008). 
9.2 Role of myeloid-derived suppressor cells 
Accumulation of MDSCs in cancer patients is an immune evasion mechanism. MDSCs were 
found to be elevated in peripheral blood of solid tumors including breast, colon, prostrate, 
hepatocellular and esophageal carcinomas. It was also shown that increase of MDSCs in 
solid tumors is stage-dependent. Stage IV solid tumor patients showed increased level of 
MDSCs which correlated with metastatic tumor burden (Diaz-Montero et al., 2009). Early 
stage breast cancer patients who received cyclophosphamide plus doxorubicin also had 
increased level of MDSCs. In multiple myeloma, information about MDSCs is lacking. 
However, a recent study showed significant increase of MDSCs in multiple myeloma 
patients (Brimnes et al., 2010). This study identified MDSCs as CD14+HLADR-/low, which 
is contradictory to other studies. In our study, we identified MDSCs as 
CD33+CD11b+CD14-HLADR-. Cells with this phenotype were elevated in multiple 
myeloma patients and also an increasing trend was showed in monoclonal gammopathy of 
undetermined significance patients compared to healthy subjects (Muthu Raja et al., 2011). 
Due to limited studies on MDSCs of myeloma patients, no strong conclusion could be 
forwarded. However, studies have shown increased level of MDSCs. Further studies are 
required to prove their functional activity. 
10. Therapeutic targeting of regulatory and suppressor cells to enhance  
anti-tumor responses 
Treg cells favored as a potential target in various cancers to enhance the anti-tumor 
responses. Chemotherapy agents such as fludarabine and cyclophosphamide were reported 
to reduce Treg cell numbers in animal models. Cyclophosphamide plus fludarabine and 
high dose IL-2 treatment was given to metastatic melanoma patients where transient 
decrease in Treg cells was observed (Powell et al., 2007). Use of chemotherapeutic agents to 
target Treg cells is relatively unspecific approach but targeting CD25 was found to be more 
selective in hitting Treg cells than chemotherapies. Various preclinical trials have shown 
that depletion of Treg cells via specific monoclonal antibodies targeting CD25 in 
combination with adoptive T cell transfer, denileukin diftitox (a fusion protein of diphtheria 
toxin and IL-2) and LMB-2 (a fusion protein of a single-chain Fv fragment of an anti-CD25 
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antibody and the bacterial pseudomonas exotoxin A or 3) enhanced the anti-tumor 
immunity (Attia et al., 1997; Knutson et al., 2006; Litzinger et al., 2007; Shimizu et al., 1999). 
Translation of denileukin diftitox and LMB-2 into clinical studies along with vaccination 
showed efficient improvement in anti-tumor response plus reduced frequency of Treg cells 
in various cancers, including metastatic renal cell carcinoma, melanoma and colorectal 
carcinoma. Targeting CTLA-4 molecule is not a precise approach because both effector T 
cells and Treg cells express CTLA-4. However, a recent animal model study showed CTLA-4 
deficient mice lacked the Treg cell mediated immune suppression (Wing et al., 2008). 
Disadvantage in blockade or depletion of Treg cells is autoimmune toxicity, which was 
observed in murine models and cancer patients (Dougan & Dranoff, 2009). Recent 
understanding of MDSCs in cancers provokes to target these suppressor cells. All-trans 
retinoic acid (ATRA) administration in animal models and in vitro study showed decreased 
number of MDSCs, activated CD4 and CD8 T cells and delayed tumor progression 
(Kusmartsev et al., 2008). ATRA administration with granulocyte macrophage colony-
stimulating factor helped in differentiation of MDSCs into myeloid dendritic cells in tumor-
bearing mice (Gabrilovich et al., 2001). In the clinical study ATRA plus IL-2 combination did 
not have impact on MDSCs of renal cell carcinoma patients. Chemotherapeutic agents, such 
as gemicitabine and 5-fluorouracil, were reported to reduce the peripheral blood MDSCs in 
animal models as well as in vitro (Le et al., 2009; Vincent et al., 2010). Cyclophosphamide 
and doxorubicin have negative impact on MDSCs of breast cancer patients (Diaz-Montero et 
al., 2009). A recent study proposed combination of cyclophosphamide with IL-2 enhanced 
the clearance of intra-tumoral Treg cells and MDSCs, and enhanced the generation of 
myeloid inflammatory cells which lack the suppressive function (Medina-Echeverz et al., 
2011). STAT-3 is a key regulatory molecule in MDSCs, and this molecule is constitutively 
expressed by malignant cells. There are several STAT-3 inhibitory molecules under 
investigation. Sunitinib is one of the STAT-3 inhibitors which influence the phosphorylation 
of STAT-3 via tyrosine kinase; additionally, it has anti-angiogenic property. Currently, 
Sunitinib is under investigation for its efficiency on MDSCs (Ko et al., 2009). These 
observations are showing the efficiency of various inhibitors and chemotherapy agents to 
hinder the regulatory and suppressor cells in vitro and in pre-clinical trials. Unfortunately, 
clinical trials did not show flourishing impact in all cancers. This might be due to 
autoimmune toxicities caused by depletion or targeting of Treg cells. Approach of hitting 
the Treg cells needs further investigation; it is essential to target specifically the tumor 
associated Treg cells not the global Treg cells which might cause imbalance in the immune 
homeostasis. 
11. Conclusion 
Large evidence is available in hematological malignancies and solid tumors for elevated 
level of various regulatory and suppressor cells which impede anti-tumor responses. 
Therefore, targeting the regulatory cells could be a useful strategy to enhance the anti-tumor 
immunity. Approaches of depletion or inhibition of regulatory cells showed countable 
benefits in pre-clinical and clinical studies of some cancers including renal cell carcinoma, 
metastatic melanoma and colorectal carcinoma. Targeting regulatory T cells in a non-specific 
approach might cause detrimental autoimmune toxicities which is the key issue. Further 
studies are necessary to identify tumor associated regulatory cells which will enhance the 
depletion of specific regulatory cells but not the global population of regulatory cells. 
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Moreover, characterization of regulatory cells in humans is an ambiguous aspect due to lack 
of precise markers. Studies are needed to disclose specific characterization marker for 
human Treg cells, so that results do not vary between groups. In multiple myeloma, 
immunotherapeutic targeting of tumor cells at the pre-clinical and clinical studies showed 
remarkable immunological as well clinical responses in some cohort of patients. When 
compared to non-hematological malignancies, there are no clinical trials performed to target 
regulatory cells in myeloma patients. Investigations are required with the inclusion of pre-
clinical and clinical studies in myeloma via combinational approach of targeting tumor cells 
as well regulatory cells. This approach might overcome tumor induced immunosuppression 
in myeloma patients. 
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